* Organon & Co reported quarterly adjusted earnings of 87 cents per share for the quarter ended September 30, identical to the same quarter last year. The mean expectation of eight analysts for the quarter was for earnings of 90 cents per share. Wall Street expected results to range from 78 cents to $1.11 per share.
* Revenue rose 4.1% to $1.58 billion from a year ago; analysts expected $1.56 billion.
* Organon & Co's reported EPS for the quarter was $1.38.
* The company reported quarterly net income of $359 million.
* Organon & Co shares had fallen by 6.3% this quarter and gained 24.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 13.5% in the last three months.
* In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and 2 "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "hold"
Wall Street's median 12-month price target for Organon & Co is $24.00 This summary was machine generated from LSEG data November 1 at 03:44 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.90 0.87 Missed
Jun. 30 2024 1.08 1.12 Beat
Mar. 31 2024 0.97 1.22 Beat
Dec. 31 2023 0.83 0.88 Beat
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。